Brokerages Set ProQR Therapeutics (NASDAQ:PRQR) PT at $7.60

Shares of ProQR Therapeutics (NASDAQ:PRQR) have earned a consensus recommendation of “Buy” from the five brokerages that are presently covering the company, MarketBeat reports. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $7.60.

A number of equities research analysts have weighed in on the company. Raymond James raised ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their price objective for the company from $6.00 to $14.00 in a report on Tuesday, October 29th. JMP Securities restated a “market outperform” rating and issued a $8.00 price target on shares of ProQR Therapeutics in a research note on Thursday, December 12th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of ProQR Therapeutics in a research report on Thursday, December 12th. Chardan Capital reissued a “buy” rating and issued a $4.00 target price on shares of ProQR Therapeutics in a report on Thursday, December 12th. Finally, StockNews.com cut shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 28th.

Institutional Trading of ProQR Therapeutics

A number of institutional investors have recently bought and sold shares of PRQR. OneDigital Investment Advisors LLC increased its position in shares of ProQR Therapeutics by 37.0% in the third quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 15,550 shares in the last quarter. BNP Paribas Financial Markets grew its stake in ProQR Therapeutics by 14.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 7,300 shares during the last quarter. Finally, Privium Fund Management B.V. grew its stake in ProQR Therapeutics by 4.4% in the 2nd quarter. Privium Fund Management B.V. now owns 5,580,725 shares of the biopharmaceutical company’s stock valued at $9,208,000 after acquiring an additional 236,279 shares during the last quarter. 32.65% of the stock is currently owned by hedge funds and other institutional investors.

ProQR Therapeutics Stock Down 12.7 %

Shares of ProQR Therapeutics stock opened at $2.47 on Thursday. The firm has a market cap of $201.75 million, a price-to-earnings ratio of -8.13 and a beta of 0.24. ProQR Therapeutics has a 52-week low of $1.61 and a 52-week high of $4.62. The company’s 50-day simple moving average is $3.40 and its 200-day simple moving average is $2.40.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).